ADTX:NSD-Aditxt Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.27

Change

+0.02 (+6.68)%

Market Cap

USD 0.01B

Volume

0.20M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Aditxt Inc (ADTX) Stock Analysis:
Based on the Aditxt Inc stock forecasts from 0 analysts, the average analyst target price for Aditxt Inc is not available over the next 12 months. Aditxt Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aditxt Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Aditxt Inc’s stock price was USD 0.27. Aditxt Inc’s stock price has changed by -0.41% over the past week, -28.84% over the past month and -88.36% over the last year.

No recent analyst target price found for Aditxt Inc
No recent average analyst rating found for Aditxt Inc

About

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed a ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.05 (-0.31%)

USD71.36B 9.16 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+3.10 (+1.23%)

USD64.54B 26.63 18.23
MRNA Moderna Inc

+5.67 (+4.12%)

USD54.78B 4.05 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+10.81 (+6.88%)

USD36.74B 3.67 1.75
SGEN Seagen Inc

-0.37 (-0.26%)

USD26.32B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.84 (+2.84%)

USD19.31B 46.16 5.06
ARGX argenx SE

+15.26 (+5.01%)

USD17.59B N/A N/A
INCY Incyte Corporation

+0.95 (+1.29%)

USD16.26B 17.19 22.08

ETFs Containing ADTX

Symbol Name Weight Mer Price(Change) Market Cap
EXH8:F iShares (DE) I - iShares .. 14.30 % 0.46 %

-1.16 (-3.85%)

USD0.01B
EXH8:XETRA iShares (DE) I - iShares .. 14.30 % 0.46 %

-0.47 (-1.60%)

USD0.01B
XESD:F Xtrackers - Spain UCITS E.. 7.92 % 0.30 %

-0.26 (-1.33%)

USD0.06B
XESP:F Xtrackers Spain UCITS ETF.. 7.92 % 0.30 %

-0.30 (-1.23%)

USD0.06B
XESD:XETRA Xtrackers - Spain UCITS E.. 7.92 % 0.30 %

-0.15 (-0.76%)

USD0.06B
XESP:XETRA Xtrackers Spain UCITS ETF.. 7.92 % 0.22 %

-0.18 (-0.75%)

USD0.05B
WTIM:F WisdomTree Issuer ICAV - .. 5.21 % 0.29 %

-0.82 (-3.91%)

USD0.06B
WTIM:XETRA WisdomTree Issuer ICAV - .. 5.21 % 0.29 %

-0.26 (-1.27%)

USD0.04B
WSRD:CA Wealthsimple Developed Ma.. 2.06 % 0.28 %

+0.17 (+0.69%)

N/A
FCIQ:CA Fidelity International Hi.. 1.85 % 0.45 %

+0.11 (+0.37%)

USD0.43B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.64% 43% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.64% 43% F 23% F
Trailing 12 Months  
Capital Gain -88.46% 9% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.46% 9% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.24% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.24% 11% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 34.89% 79% C+ 45% F
Risk Adjusted Return -75.21% 11% F 4% F
Market Capitalization 0.01B 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 86% B 96% A
Price/Book Ratio 1.28 60% D- 62% D-
Price / Cash Flow Ratio -0.51 15% F 52% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -437.63% 5% F 3% F
Return on Invested Capital -371.26% 3% F 4% F
Return on Assets -115.23% 3% F 1% F
Debt to Equity Ratio 1.08% 83% B 86% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.74 87% B+ 80% B-
Short Percent 0.99% 84% B 74% C
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.